ArticleClinical and translational radiation oncology2026
Prognosis of patients with early salvage radiotherapy and low persisting or increasing PSA levels after radical prostatectomy for prostate cancer. A retrospective comparative analysis.
Article in Clinical and translational radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Title: Prognosis of patients with early salvage radiotherapy and low persisting or increasing PSA levels after radical prostatectomy for prostate cancer. A retrospective comparative analysis. Introduction: European prostate cancer guidelines include a "weak" recommendation to add hormonal therapy (ADT) to salvage radiotherapy (SRT) for better prognosis with persistent PSA values after radical prostatectomy (RP). In this study, prognosis with persistent PSA versus a PSA increase above undetectable after RP was compared. Methods: In this retrospective study of patients who underwent SRT to the prostate bed without ADT (pre-SRT-PSA ≤ 0.3 ng/ml), 243 patients had a PSA increase from undetectable (post-op PSA ≤ 0.05 ng/ml), and 110 patients had persisting PSA after RP (post-op PSA > 0.05 ng/ml). Primary endpoints: clinical progression-free survival (PFS), biochemical PFS (BPFS), metastasis-free survival (MFS), overall survival (OS). Results: BPFS rates were 66.4% with low persistent PSA versus 71.6% with recurrent PSA (p = 0.253; median follow-up, 60 [25-92] months). The low-persistent and recurrent groups also did not differ for MFS, PFS, or OS (all p > 0.05). In univariate and multivariate analyses, T3-4 and Gleason grade 4-5 predicted BPFS; T-status, R-status (R1,2), and Gleason grade influenced PFS; Gleason grade predicted MFS; and T-status predicted OS. In multivariate analysis, PSA persistence did not predict any survival outcomes (all p > 0.05). Conclusion: Prognosis with low persistent PSA values seems comparable to that with PSA levels increasing above undetectable. In the absence of other factors, ADT could be omitted in this favorable patient group. Prospective trials are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.